BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Pancreatic cancer AND TSC1, KIAA0243, 7248, ENSG00000165699, TSC, MGC86987, LAM, hamartin
71 results:

  • 1. A case of pancreatic PEComa with prominent inflammatory cell infiltration: the inflammatory subtype is a distinct histologic group of PEComa.
    Tsukita H; Koyama K; Ishinari T; Takahashi A; Miyabe K; Umakoshi M; Yoshida M; Kudo-Asabe Y; Nishida A; Otsuka N; Yasui O; Kato I; Fukushima N; Goto A
    Diagn Pathol; 2024 Apr; 19(1):59. PubMed ID: 38622713
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Genetic disorders and insulinoma/glucagonoma.
    Marini F; Giusti F; Brandi ML
    Endocr Relat Cancer; 2024 May; 31(5):. PubMed ID: 38552306
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Epithelioid angiomyolipoma of the liver in a patient with Li-Fraumeni syndrome: a case report.
    Yang Y; Lee J; Woo CG; Lee OJ; Son SM
    Diagn Pathol; 2024 Jan; 19(1):16. PubMed ID: 38243242
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. An Integrated Multi-Omics Analysis Identifying Immune Subtypes of pancreatic cancer.
    Su Y; Wang F; Lei Z; Li J; Ma M; Yan Y; Zhang W; Chen X; Xu B; Hu T
    Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203311
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Elevated FBXL6 expression in hepatocytes activates VRK2-transketolase-ROS-mTOR-mediated immune evasion and liver cancer metastasis in mice.
    Zhang J; Lin XT; Yu HQ; Fang L; Wu D; Luo YD; Zhang YJ; Xie CM
    Exp Mol Med; 2023 Oct; 55(10):2162-2176. PubMed ID: 37653031
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Tuberous sclerosis complex mutations in patients with pancreatic neuroendocrine tumors. Observations on phenotypic and treatment-related associations.
    Navale P; Chatterjee D; Itani M; Trikalinos NA
    Virchows Arch; 2023 Aug; 483(2):167-175. PubMed ID: 37354253
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. A systems biology approach to define mechanisms, phenotypes, and drivers in PanNETs with a personalized perspective.
    Werle SD; Ikonomi N; Lausser L; Kestler AMTU; Weidner FM; Schwab JD; Maier J; Buchholz M; Gress TM; Kestler AMR; Kestler HA
    NPJ Syst Biol Appl; 2023 Jun; 9(1):22. PubMed ID: 37270586
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Interim Analysis of a Prospective Validation of 2 Blood-Based Genomic Assessments (PPQ and NETest) to Determine the Clinical Efficacy of
    Bodei L; Raj N; Do RK; Mauguen A; Krebs S; Reidy-Lagunes D; Schöder H
    J Nucl Med; 2023 Apr; 64(4):567-573. PubMed ID: 36396457
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Primary retroperitoneal PEComa: an incidental finding.
    Marinho BM; Canha AG; Silva DS; Silva JDP
    BMJ Case Rep; 2022 Nov; 15(11):. PubMed ID: 36368730
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Turning up the heat on non-immunoreactive tumors: autophagy influences the immune microenvironment in pancreatic cancer.
    Lu SY; Hua J; Liu J; Wei MY; Liang C; Meng QC; Zhang B; Yu XJ; Wang W; Xu J
    BMC Med Genomics; 2022 Oct; 15(1):218. PubMed ID: 36261830
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Evaluation of the anti-diabetic effect of biogenic silver nanoparticles and intervention in PPARγ gene regulation.
    Sengani M; V B; Banerjee M; Choudhury AA; Chakraborty S; Ramasubbu K; Rajeswari V D; Al Obaid S; Alharbi SA; Subramani B; Brindhadevi K
    Environ Res; 2022 Dec; 215(Pt 3):114408. PubMed ID: 36154863
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Prognostic Value, Immune Signature, and Molecular Mechanisms of the PHLDA Family in pancreatic Adenocarcinoma.
    Duan Y; Du Y; Gu Z; Zheng X; Wang C
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142223
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Neuroendocrine neoplasms in the context of inherited tumor syndromes: a reappraisal focused on targeted therapies.
    Ruggeri RM; Benevento E; De Cicco F; Fazzalari B; Guadagno E; Hasballa I; Tarsitano MG; Isidori AM; Colao A; Faggiano A;
    J Endocrinol Invest; 2023 Feb; 46(2):213-234. PubMed ID: 36038743
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Whole-exome sequencing analysis of NSCLC reveals the pathogenic missense variants from cancer-associated genes.
    Kumar S U; Balasundaram A; Cathryn R H; Varghese RP; R S; R G; Younes S; Zayed H; Doss C GP
    Comput Biol Med; 2022 Sep; 148():105701. PubMed ID: 35753820
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. E2F7 promotes mammalian target of rapamycin inhibitor resistance in hepatocellular carcinoma after liver transplantation.
    Ling S; Zhan Q; Jiang G; Shan Q; Yin L; Wang R; Que Q; Wei X; Xu S; Yu J; Zhou W; Zhang L; Bao J; Ye Q; Su R; Wei R; Liu J; Chen K; Wang J; Xie H; Zheng S; He X; Xiang J; Xu X
    Am J Transplant; 2022 Oct; 22(10):2323-2336. PubMed ID: 35729702
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Tuberous sclerosis complex-associated nonfunctional pancreatic neuroendocrine tumors: Management and surgical outcomes.
    Evans LM; Geenen KR; O'Shea A; Hedgire SS; Ferrone CR; Thiele EA
    Am J Med Genet A; 2022 Sep; 188(9):2666-2671. PubMed ID: 35612824
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Mechanistic Target of Rapamycin (mTOR) Inhibitors.
    Wang D; Eisen HJ
    Handb Exp Pharmacol; 2022; 272():53-72. PubMed ID: 35091825
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Rare manifestations and malignancies in tuberous sclerosis complex: findings from the TuberOus SClerosis registry to increAse disease awareness (TOSCA).
    Sauter M; Belousova E; Benedik MP; Carter T; Cottin V; Curatolo P; Dahlin M; D'Amato L; d'Augères GB; de Vries PJ; Ferreira JC; Feucht M; Fladrowski C; Hertzberg C; Jozwiak S; Lawson JA; Macaya A; Marques R; Nabbout R; O'Callaghan F; Qin J; Sander V; Shah S; Takahashi Y; Touraine R; Youroukos S; Zonnenberg B; Jansen A; Kingswood JC;
    Orphanet J Rare Dis; 2021 Jul; 16(1):301. PubMed ID: 34229737
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Sirolimus-based immunosuppression improves the prognosis of liver Transplantation Recipients with low tsc1/2 expression in hepatocellular carcinoma beyond the Milan Criteria.
    Ye Q; Ling S; Jiang G; Shan Q; Xu S; Zhan Q; Wu Y; Liu Y; Zheng S; Xu X
    Eur J Surg Oncol; 2021 Oct; 47(10):2533-2542. PubMed ID: 33902956
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Role of tsc1 in physiology and diseases.
    Mallela K; Kumar A
    Mol Cell Biochem; 2021 Jun; 476(6):2269-2282. PubMed ID: 33575875
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 4.